SPY399.11-2.61 -0.65%
DIA320.85-1.39 -0.43%
IXIC11,676.84-128.16 -1.09%

Stealth BioTherapeutics' Phase 2 Eye Disease Trial Fails to Meet Primary Endpoints; Shares Fall

MT Newswires · 05/02/2022 05:04

Please log in to view news